Mission Therapeutics has begun Phase 1b dosing of MTX325, an orally bioavailable, brain-penetrant USP30 inhibitor designed to restore mitophagy — the selective clearance of damaged mitochondria — in patients with mild to moderate idiopathic Parkinson's disease. The 36-participant trial across the UK, Europe and Australia will assess safety, tolerability, biomarkers and imaging, with proof-of-mechanism data expected in late 2027. Targeting mitochondrial quality control rather than dopaminergic symptom replacement places this program among the first clinical tests of a core aging mechanism in neurodegeneration.
Key Points
- First patient dosed in Phase 1b trial of USP30 inhibitor MTX325
- Drug targets mitophagy to clear dysfunctional mitochondria in neurons
- 36 participants enrolled; proof-of-mechanism readout expected late 2027
Longevity Analysis
Accumulation of damaged mitochondria is a shared feature of neurodegeneration and biological aging, and the capacity to recycle them declines with age across most tissues. A drug that restores this internal clearance process — rather than compensating for lost dopamine signalling — tests whether removing cellular interference can alter the trajectory of a progressive disease. Imaging and biomarker endpoints in this trial will also indicate how reliably mitochondrial turnover can be measured in living patients, which matters for any intervention aimed at preserving energy production and neural resilience over decades.
Original published by LT Wire.